Belimumab in a Patient with Systemic Lupus Erythematosus with Juvenile Onset and Steroid-induced Diabetes: Clinical Case

Background. The management of children with systemic lupus erythematosus (SLE) is usually associated with lifelong systemic glucocorticoids administration and, thereby, high risk of serious side effects, including steroid-induced diabetes. The belimumab (B-lymphocyte stimulator inhibitor) administra...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria I. Kaleda, Irina P. Nikishina, Alesya V. Firsa
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2023-12-01
Series:Вопросы современной педиатрии
Subjects:
Online Access:https://vsp.spr-journal.ru/jour/article/view/3356
Tags: Add Tag
No Tags, Be the first to tag this record!